Author(s): Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, et al.
Objective: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For the first time in the United States, we present preliminary results of the treatment with Lutetium (177)(Lu) DOTATATE in patients with progressive NETs.
Methods: Thirty-seven patients with grade 1 and grade 2 disseminated and progressive gastroenteropancreatic NET were enrolled in a nonrandomized, phase 2 clinical trial. Repeated cycles of 200 mCi (7.4 GBq; ±10%) were administered up to the cumulative dose of 800 mCi (29.6 GBq; ±10%).
Results: Among 32 evaluable patients, partial response and minimal response to treatment were seen in 28% and 3%, respectively, and stable disease was seen in 41% of patients. A total of 28% had progressive disease. A response to treatment was significantly associated with lower burden of disease in the liver. No significant acute or delayed hematologic or kidney toxicity was observed. An impressive improvement of performance status and quality of life were seen after Lu-DOTATATE therapy.
Conclusions: Treatment with multiple cycles of (177)Lu-DOTATATE peptide receptor radionuclide therapy is well tolerated. This treatment results in control of the disease in most patients, whereas systemic toxicities are limited and reversible. Quality of life is also improved.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/24632546
Author(s): Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, et al.
Author(s): Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al.
Author(s): Fouladi M, Hunt DL, Pollack IF, Dueckers G, Burger PC, et al.
Author(s): Nelson D, Nelson J, Davis D, Chang C, Griffins T, et al.
Author(s): Parvez T
Author(s): Reese TS, Karnovsky MJ
Author(s): Kreuter J
Author(s): Kreuter J.
Author(s): Humm JL, Sartor O, Parker C, Bruland OS, Macklis R
Author(s): Shore ND
Author(s): Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al.
Author(s): Chanda N, Kan P, Watkinson LD, Shukla R, Zambre A, et al.
Author(s): Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P
Author(s): Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, et al.
Author(s): Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, et al.
Author(s): Bhattacharyya S, Singh RD, Pagano R, Robertson JD, Bhattacharya R, et al.
Author(s): Kudgus RA, Walden CA, McGovern RM, Reid JM, Robertson JD, et al.
Author(s): Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, et al.
Author(s): McLaughlin MF, Robertson D, Pevsner PH, Wall JS, Mirzadeh S, et al.
Author(s): Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, et al.
Author(s): McLaughlin MF, Woodward J, Boll RA, Wall JS, Rondinone AJ, et al.
Author(s): Miller DC, Koslow M, Budzilovich GN, Burstein DE
Author(s): Joshi RP, Hu Q
Author(s): Joshi RP, Schoenbach KH
Author(s): Roth CC, Tolstykh GP, Payne JA, Kuipers MA, Thompson GL